针对BRAF突变转移性黑色素瘤的向治疗或免疫治疗:西班牙中心十年的经验

Chen Sun1, Sofia España2, Nina Richarz3

  • 1Department of Radiation Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Frontiers in oncology
|March 7, 2024
PubMed
概括

对于晚期BRAF突变黑色素瘤,一线免疫疗法与向治疗 (BRAF/MEKi) 相比,显著改善了无进展生存率 (PFS) 和整体生存率 (OS). 向治疗显示出更高的客观响应率 (ORR).

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K